Long-term intraocular pressure-lowering efficacy and safety of ripasudil-brimonidine fixed-dose combination for glaucoma and ocular hypertension: a multicentre, open-label, phase 3 study.

PURPOSE: To evaluate the long-term efficacy and safety of ripasudil-brimonidine fixed-dose combination (RBFC), a new intraocular pressure (IOP)-lowering medication for glaucoma and ocular hypertension (OHT). METHODS: This prospective, multicentre (23 sites in Japan), open-label study enrolled patients with primary open-angle glaucoma (POAG), OHT or exfoliative glaucoma and assigned them to one of four combination therapy cohorts, based on previous treatment(s) received: prostaglandin (PG) analogue (Cohort 1); PG analogue and beta-adrenoceptor blocker (ß-blocker) (Cohort 2); PG analogue, ß-blocker and carbonic anhydrase inhibitor (Cohort 3); or other/no treatment (Cohort 4). After a ≥ 4-week screening period, eligible patients received twice-daily RBFC for 52 weeks in addition to the treatments they were already receiving. Efficacy was assessed by change in IOP from baseline through week 52. Adverse events and adverse drug reactions (ADRs) were monitored throughout. RESULTS: In total, 179 patients from Cohort 1 (n = 48), Cohort 2 (n = 44), Cohort 3 (n = 41) and Cohort 4 (n = 46) entered the RBFC treatment period. For all cohorts, mean IOP was significantly reduced at 11:00 (2 h after instillation of RBFC) through week 52 with the changes from baseline at week 52 of - 2.7 to - 4.1 mmHg across cohorts; all p < 0.001. Common ADRs were conjunctival hyperaemia (58%), allergic conjunctivitis (18%) and blepharitis (17%), most of which were mild in severity. CONCLUSION: These data demonstrated the long-term efficacy and safety of RBFC, both alone and in combination with other anti-glaucoma agents. RBFC may offer a new treatment option for the long-term management of glaucoma and OHT. TRIAL REGISTRATION: Japan Registry of Clinical Trials Identifier: jRCT2080225063. DATE OF REGISTRATION: 17 February 2020.

A Case of Pigmented Paravenous Retinochoroidal Atrophy With Retinitis Pigmentosa.

Chorioretinal atrophy with pigmentation along the retinal veins was observed in the right fundus of a 49-year-old patient. Extensive retinitis pigmentosa (RP) was observed in the left eye. Dynamic quantitative visual field testing revealed a scotoma in the right eye that corresponded to the area of ​​retinochoroidal atrophy and afferent visual field constriction was observed on the left eye. An electroretinogram test revealed that the right eye showed attenuated type and the left eye showed negative type. Thus, the conditions of his right eye and left eye were diagnosed as pigmented paravenous retinochoroidal atrophy (PPRCA) and RP, respectively. Thus, there may be a higher proportion of PPRCA patients with unilateral RP than expected.

A multicenter study of ocular inflammation after COVID-19 vaccination.

PURPOSE: To report the characteristics of a case series of ocular inflammatory events following COVID-19 vaccination in Japan. STUDY DESIGN: Retrospective multicenter study METHODS: In this retrospective multicenter survey, a questionnaire was sent to 16 Japanese hospitals that had uveitis specialty clinics. Information on patients who developed ocular inflammatory events within 14 days of COVID-19 vaccination between February 2021 and December 2021 was collected. RESULTS: Thirty-seven patients were diagnosed with ocular inflammatory events following COVID-19 vaccination. The mean age was 53.4 ± 16.4 years (range, 26-86 years), and the mean time to onset after vaccination was 6.3 ± 4.2 days (range, 1-14 days). Vogt-Koyanagi-Harada disease (VKH) was the most common event (n = 17 patients, 46%), followed by anterior uveitis (n = 6), infectious uveitis (n = 3), acute zonal occult outer retinopathy (AZOOR) (n = 2), sarcoidosis-associated uveitis (n = 1), acute posterior multifocal placoid pigment epitheliopathy (APMPPE) (n = 1), optic neuritis (n = 1), multiple evanescent white dot syndrome (MEWDS) (n = 1), Posner-Schlossman syndrome (n = 1), and unclassified uveitis (n = 4). Twenty-eight cases occurred after BNT162b2 vaccination (Pfizer-BioNTech) and 8 after mRNA-1273 vaccination (Moderna), whilst 1 patient had no information about vaccine type. CONCLUSIONS: COVID-19 vaccination can be related to various types of ocular inflammatory events. When we encounter patients with ocular inflammatory disease, we should consider that it may be an adverse effect of COVID-19 vaccination.

Effects of Antihistamine-Releasing Contact Lenses on Severe Allergic Conjunctivitis.

Half of the patients who used CL daily did not wish to switch to spectacles even with ocular-allergic symptoms and findings. Therefore, continued CL use with suppressed ocular allergy can improve productivity and quality of life for CL users. This study described the clinical courses of CL users with ocular-allergic conjunctivitis who started ARCL trials on their eyes. Diagnoses of the seven understudied cases were AKC in 3, VKC in 2, SAC in 1, and CLPC in 1 case. All seven cases had myopia. Following the use of ARCL, six patients except for case 7 were satisfied, and objective findings were judged to be well-controlled. ARCL can be a useful tool for CL users with allergic conjunctivitis. However, ARCL should be introduced after allergic conjunctivitis is controlled or becomes asymptomatic. Furthermore, ARCL should be immediately discontinued if ocular-allergic symptoms flare after introducing ARCL.

A Case of Immunoglobulin G4-Related Scleritis and Pneumonia Initially Diagnosed as Eosinophilic Pneumonia.

Immunoglobulin G4 (IgG4)-positive plasma cells play a pivotal role in the pathogenesis of IgG4-related diseases, in which fibrosis is observed in various organs. Lesions often develop in the lacrimal gland and orbit; however, uveitis and scleritis are also noticed. We present the case of a 55-year-old woman who was diagnosed with eosinophilic pneumonia in November 2021 at the Department of Collagen Disease of another hospital. She was treated with 25 mg of oral prednisolone. On January 11, 2022, when the dose of prednisolone was reduced to 7.5 mg, she began complaining of conjunctival hyperemia in the left eye, and a few days later, eye pain was also reported. On January 17, she visited an ophthalmology clinic and was prescribed betamethasone and tacrolimus eye drops, and was subsequently admitted to our hospital. The blood test results showed a high IgG4 level. We consulted the collagen disease physician to evaluate her previous data. The serum IgG4 level collected on December 6, 2021, was 608 mg/dL, and a re-examination of the bronchial biopsy tissues on December 2, 2021, confirmed 48% of IgG4-positive cells. Thus, pulmonary lesions appeared to be IgG4-related pathologies. Increasing the oral prednisolone dose to 30 mg improved the scleritis. As seen in this case, the possibility of an IgG4-related disease should be considered when scleritis is observed in a patient diagnosed with eosinophilic pneumonia.

A Case of Vernal Keratoconjunctivitis With Growth Hormone Deficiency.

Hormonal abnormalities are considered to play a role in the development of vernal keratoconjunctivitis (VKC). However, little is known whether about growth hormone (GH) is related to VKC development. The patient was an 11-year-old male with VKC treated with 0.1% betamethasone eye drops and 0.1% cyclosporin eye drops. The papillary growth of both superior and inferior palpebral conjunctiva worsened, and masses started to appear at the lower palpebral margin. He was referred to our hospital and was treated with 0.1% tacrolimus and 0.1% fluorometholone. Six weeks later, the condition improved remarkably. At this timepoint, we noticed the patient's short stature and asked again about his past history. Two years ago, he was diagnosed with GH deficiency (GHD), which had been treated with somatropin in a pediatric clinic. Thus, it is necessary to keep in mind the possibility of GHD when treating VKC patients.

Efficacy of Proactive Topical Antihistamine Use in Patients with Seasonal Allergic Conjunctivitis.

INTRODUCTION: Topical antihistamines are often instilled symptomatically to control patients' eye allergy symptoms. The purpose of this study was to evaluate the effectiveness of proactive and as-needed use of antihistamine eye drops in controlling symptoms and to examine whether proactive use may improve quality of life (QOL). METHODS: This was a prospective, multicenter, cohort study in Japan. We classified 418 patients who had developed certain symptoms and used antihistamine eye drops for 2 weeks into two groups: those who used the drops at the required frequency at a fixed time (proactive use) and those who used them as-needed. The Japanese Allergic and Conjunctival Diseases Quality of Life Questionnaire (JACQLQ) and Ten-Item Personality Inventory were used to evaluate QOL and personality. Participants' QOL was evaluated using JACQLQ scores after matching of baseline characteristics using propensity score analysis. RESULTS: After propensity score matching, 115 "proactive" and 115 "as-needed" patients were analyzed. After treatment, in "as-needed" patients, the overall QOL scale was 1.66 (95% CI 1.55-1.78); in "proactive" patients, the overall QOL scale was 1.34 (95% CI 1.23-1.46) and was significantly improved compared with the "as-needed" patients (analysis of covariance, P = 0.002). Furthermore, proactive use significantly alleviated depression (P = 0.03). This improvement of QOL was independent of improvement of the clinical sign scores. CONCLUSION: Proactive use of topical antihistamine may serve as an effective means for improving QOL of patients with seasonal allergic conjunctivitis. TRIAL REGISTRATION: University Hospital Medical Information Network (UMIN) 000039554.

Executive summary: Japanese guidelines for allergic conjunctival diseases 2021.

Allergic conjunctival disease (ACD) is an inflammatory disease of the conjunctiva that is mainly caused by type I hypersensitivity response to allergens and accompanied by subjective symptoms and other findings induced by antigens. ACD is classified as allergic conjunctivitis, atopic keratoconjunctivitis, vernal keratoconjunctivitis, and giant papillary conjunctivitis. This article summarizes the third edition of the Japanese guidelines for allergic conjunctival diseases published in 2021 and outlines the diagnosis, pathogenesis, and treatment of ACD. Since the introduction of immunosuppressive eye drops, the treatment strategies for severe ACDs have significantly changed. To clarify the recommended standard treatment protocols for ACD, the advantages and disadvantages of these treatments were assessed using clinical questions, with a focus on the use of steroids and immunosuppressive drugs. This knowledge will assist healthcare providers and patients in taking an active role in medical decision making.

A Case of Immunoglobulin G4-Related Ophthalmic Disease With Unilateral Visual Field Impairment.

A 76-year-old man receiving maintenance therapy with oral steroids for immunoglobulin G4 (IgG4)-related disease presented to our hospital with the chief complaint of visual disturbance. His best corrected visual acuities of the right and left eye were 1.2 and 0.7, respectively. Humphrey visual field test revealed inferior auriculotemporal one-quarter blindness in the left eye. After detailed history-taking for IgG4-related disease, clinical diagnosis based on imaging revealed the marked pituitary/pituitary stalk enlargement with associated optic chiasm compression. Based on the history and initial evaluation findings, a diagnosis of IgG4-related ophthalmic disease was made. Intensified steroid therapy was performed, which led to symptom resolution. IgG4-related diseases are considered in the differential diagnosis when bilateral hemianopsia is observed. When unilateral visual acuity and visual field defects are present, IgG4-related diseases and other organ disorders should be considered.

A Case of Orbital Apex Syndrome Related to Herpes Zoster Ophtalmicus.

Orbital apex syndrome (OAS) is a rare disease. One of the causes of OAS is herpes zoster ophthalmicus (HZO). A 73-year-old man developed herpes zoster around the right eye, and oral amenamevir treatment was given for seven days. The right eyelid ptosis was observed on the third day, and right eye movement was restricted in all directions on the ninth day. His eyesight was also poor, and he was diagnosed with OAS associated with HZO. Cerebrospinal fluid examination revealed mononuclear cell increase; however, VZV-DNA was not detected. Intravenous infusion of acyclovir and oral prednisolone administration were started. Two weeks after the start of treatment, ptosis, eye movements, and visual acuity improved. If HZO is found, it is necessary to consider the possibility of developing OAS.

A Case of Birdshot Chorioretinopathy following Varicella Zoster Virus-Induced Progressive Retinal Necrosis in the Contralateral Eye.

Birdshot chorioretinopathy is an immune-mediated ocular inflammatory disease of the retina. We report a case of birdshot chorioretinopathy in one eye following progressive retinal necrosis caused by varicella zoster virus (VZV) in the contralateral eye. A 79-year-old female patient complained of decreased vision due to anterior chamber inflammation and vitreous opacity in the left eye starting 10 days earlier. Acute retinal necrosis was suspected and polymerase chain reaction analysis was performed using the anterior chamber aqueous. VZV DNA was detected, and antiviral drugs and steroids were systemically administered together with local therapy. As retinal necrotic changes and retinal detachment gradually developed, vitrectomy and silicone oil tamponade were performed. Despite these procedures, retinal necrosis gradually progressed. Eventually, extensive retinochoroidal atrophy resembling progressive outer retinal necrosis was observed. Two years and 4 months after onset, anterior chamber inflammation and white spots of the retina started to appear in the right eye. The number of white spots gradually increased all around the retina, regardless of systemic treatment with acyclovir and prednisolone. The fundus findings seemed consistent with birdshot chorioretinopathy. Diseases exhibiting white dots in the retina, such as sarcoidosis, were excluded. Ss-OCT examination revealed destruction of the layer structure mainly in the outer layers of the retina and a section of a white dot revealed that the retina appeared to be pulled into the RPE. To the best of our knowledge, this is the first report of birdshot chorioretinopathy in one eye after the onset of VZV-induced retinal necrosis in the contralateral eye.

Autoimmune Retinopathy Caused by Anti-Paraneoplastic Antigen MA2: A Case Study.

Autoimmune retinopathy is a cause of unexplained visual impairment and visual field impairment, which are often related with life-threatening cancers. Here, we report a case of autoimmune retinopathy positive for anti-paraneoplastic antigen MA2 (PNMA2) antibody in serum. Visual acuity and field were impaired, and OCT and ERG were performed. No abnormalities were observed in OCT, but a marked decrease in pyramidal response was observed in ERG. Paraneoplastic antigen-related antibodies in the serum were tested, and PNMA2 was positive. Systemic evaluation to search for the presence of cancer was conducted by specialists treating cancer. However, cancers were not detected, but bladder and prostate cancer were identified 3 years later, and anti-PNMA2 antibodies were again positive in the serum. Although there have been no reports on PNMA2-related retinopathy, the possibility of the paraneoplastic syndrome should be kept in mind when retinopathy of unknown cause is observed.

A case of IgG4-related conjunctival tumor with severe systemic allergy treated with antibodies against cytokine receptors.

Purpose: To present a case of IgG4-related conjunctival tumor in which anti-IL-5 receptor alpha-chain and anti-IL-4 receptor alpha-chain antibodies were administered for eosinophil sinusitis and severe bronchial asthma, but conjunctivitis could not be controlled. Observations: A 53-year-old male patient started to receive anti-IL-5 receptor alpha chain antibody to treat eosinophilic sinusitis and eosinophilic severe bronchial asthma. Several months later, proliferative changes of the right palpebral conjunctiva appeared and were treated with tacrolimus and betamethasone eye drops. However, the findings gradually worsened and the right upper palpebral conjunctiva remained exposed. Exposed tissue was resected and histopathological examinations revealed the presence of IgG4 positive cells (10>/400HPF). Anti-IL-5 receptor alpha chain antibody treatment was stopped and changed to prednisolone. The findings improved and anti-IL-4 receptor alpha chain antibody was added to control eosinophilic sinusitis and eosinophilic severe bronchial asthma. The lesions worsened when the prednisolone was reduced under treatment with anti-IL-4 receptor alpha-chain antibody. Conclusions and importance: In this case, the proliferative changes could not be suppressed by treatment targeting IL-5R receptor alpha-chain and IL-4R receptor alpha-chain, suggesting that the patient had VKC-like severe allergic conjunctivitis as a manifestation of IgG4-related disease. Additionally, it should be noted that if the severe conjunctivitis cannot be suppressed by treatment with immunosuppressive eye drops or various systemic biological agents, the conjunctivitis may be a manifestation of IgG4 related disease.

Outcomes of flanged IOL fixation combined with microhook trabeculotomy.

PURPOSE: To evaluate the outcomes of flanged intraocular lens fixation combined with microhook trabeculotomy. PATIENTS AND METHODS: This study was a retrospective case series and included nine eyes of nine exfoliation glaucoma patients with subluxated lens or intraocular lens who underwent flanged intraocular lens fixation combined with microhook trabeculotomy between May 2019 and February 2020 at the Kochi University Hospital. The mean best-corrected visual acuity, intraocular pressure, and number of antiglaucoma medications were compared before and after surgery. RESULTS: The mean follow-up period was 5.67 ± 2.50 months. The mean best-corrected visual acuity improved significantly from 0.83 ± 0.72 preoperatively to 0.22 ± 0.34 at the last visit (p = 0.015). The mean intraocular pressure had significantly reduced from 27.1 ± 8.12 mmHg preoperatively to 13.2 ± 3.73 at the last visit (p = 0.008). The mean number of antiglaucoma medications decreased significantly from 4.56 ± 1.88 to 2.0 ± 1.0 at the last visit (p = 0.008). Postoperative intraocular pressure control to 21 mmHg or lower was achieved or maintained in all patients. Postoperative vitreous hemorrhage was observed in six eyes (66.7%), two of which needed reoperation. CONCLUSIONS: This study showed that flanged intraocular lens fixation combined with microhook trabeculotomy might be effective for exfoliation glaucoma with subluxated lens or intraocular lens.

Optic Neuropathy with Headache and Palpable Temporal Arteries Due to Hypertrophic Pachymeningitis Rather than Giant Cell Arteritis.

Purpose: To report a case of optic neuropathy diagnosed by color Doppler ultrasonography and Gadolinium-enhanced cerebral magnetic resonance imaging (MRI).Case report: A 79-year-old woman presented with headache and vision loss in her left eye. Although her bilateral temporal arteries were palpable and rope-like, color Doppler ultrasonography showed normal flow in both arteries with no signs of arteritis. MRI revealed increased enhancement of the pachymeninges enveloping both cerebral hemispheres, suggestive of hypertrophic pachymeningitis.Conclusion: Symptoms and laboratory data are similar for both hypertrophic pachymeningitis and giant cell arteritis (GCA). The present case suggests the utility of ultrasonography and MRI as rapid, convenient, and noninvasive tools for differential diagnosis of optic neuropathy.

Clinical profile and visual outcome of intraocular inflammation associated with cat-scratch disease in Japanese patients.

PURPOSE: To evaluate intraocular inflammation in Japanese patients with cat-scratch disease (CSD). STUDY DESIGN: Retrospective clinical chart review. PATIENTS AND METHODS: The cases of 15 consecutive patients (19 affected eyes) in Kochi Prefecture, Japan who were serologically positive for Bartonella henselae or Bartonella quintana infection in association with intraocular inflammation were reviewed. The clinical manifestations, ocular complications, and treatment modalities were recorded. The clinical charts and photographic records were also reviewed for evidence of optic disc lesions, macular star, foci of chorioretinitis, and other findings. RESULTS: Thirteen patients reported fever before or at the time of the initial presentation. Ten of 11 patients with decreased visual acuity manifested neuroretinitis, and the remaining patient showed retinochoroiditis with macular involvement. One patient with a visual field defect manifested branch retinal artery occlusion. Three patients without visual disturbance presented with fever of unknown cause. Discrete white retinal or retinochoroidal lesions were the most common findings (84% of eyes, 87% of patients), followed by retinal hemorrhage (63% of eyes, 80% of patients), optic disc lesions (63% of eyes, 73% of patients), serous retinal detachment (53% of eyes, 67% of patients), and macular star (47% of eyes, 60% of patients). CONCLUSION: White retinal or retinochoroidal foci were the most common ocular posterior segment manifestations of CSD in this patient population. A diagnosis of CSD should be suspected in patients with fever and chorioretinal white spots, and the absence of neuroretinitis or macular star does not exclude the possibility of intraocular inflammation in CSD.

[QUANTIFICATION OF CONJUNCTIVAL HYPEREMIA IN RABBITS USING ANALYSIS SOFTWARE].

BACKGROUND/PURPOSE: In a method evaluating conjunctival hyperemia using rabbits, it is common to visually grade the degree of vasodilation. However, this method is limited in evaluating consecutive value and in reproducibility. We quantified the degree of conjunctival hyperemia in rabbits as the area ratio of blood vessels by image analysis, and compared the vascular area percentage calculated by image analysis with the hyperemia score. METHODS: The conjunctiva was photographed before and after the instillation of 0.1% arachidonic acid using a digital medical scope VersaCam® (Nidek Co., Ltd.). Next, the area of the conjunctival blood vessels occupying the area of interest was calculated using hyperemia analysis software. The hyperemia score was visually graded for the degree of conjunctiva vasodilation. Furthermore, the hyperemia score and the vascular area ratio were compared. RESULTS: Fifteen minutes after the instillation of arachidonic acid, the area ratio of the blood vessels in the conjunctiva increased significantly and gradually decreased over time. This trend correlated with the hyperemia score. CONCLUSION: We found that the degree of conjunctival hyperemia in rabbits can be evaluated numerically and quantitatively. This method is considered to be useful for evaluating conjunctival hyperemia in allergic conjunctival diseases.

In Vitro and In Vivo Evaluation of Three Newly Isolated Bacteriophage Candidates, phiEF7H, phiEF14H1, phiEF19G, for Treatment of Enterococcus faecalis Endophthalmitis.

Post-operative endophthalmitis caused by Enterococcus spp. progresses rapidly and often results in substantial and irreversible vision loss. Therefore, novel alternative treatments that are effective against enterococcal endophthalmitis are required. Bacteriophage therapy has the potential to be an optional therapy for infectious diseases. Therefore, we investigated the therapeutic potential of three newly isolated enterococcal phages, phiEF7H, phiEF14H1, and phiEF19G, in E. faecalis-induced endophthalmitis. These phages could lyse the broad-range E. faecalis, including strains derived from endophthalmitis and vancomycin-resistant E. faecalis in vitro, as determined by the streak test. Morphological and genomic analyses revealed that these phages were classified into the Herelleviridae genus Kochikohdavirus. The whole genomes of these phages contained 143,399, 143,280, and 143,400 bp, respectively. Endophthalmitis was induced in mice by injection of three strains of E. faecalis derived from post-operative endophthalmitis or vancomycin-resistant strains into the vitreous body. The number of viable bacteria and infiltration of neutrophils in the eye were both decreased by intravitreous injection of phiEF7H, phiEF14H1, and phiEF19G 6 h after injection of all E. faecalis strains. Thus, these results suggest that these newly isolated phages may serve as promising candidates for phage therapy against endophthalmitis.

Miscellaneous Ocular Symptoms in a Case of Relapsing Polychondritis.

PURPOSE: To report a case of miscellaneous ocular symptoms associated with relapsing polychondritis (RP). CASE REPORT: A 58-year-old man presented with multiple ocular symptoms including both anterior and posterior scleritis, conjunctivitis, eyelid edema, eye movement disorder, keratitis, and retinopathy. Miscellaneous systemic inflammation in the right auricle as well as nasal and laryngeal cartilage was also evident together with vestibular and auditory nerve disorders. According to his clinical signs and the results of color Doppler ultrasonography, positron emission tomography and computed tomography, and a biopsy of the right auricle, we made a diagnosis of RP. CONCLUSION: Given that RP is potentially fatal, it is important that the condition be diagnosed early and treated promptly. Ophthalmologists should be aware that RP is a potential cause of recurrent and refractory multiple ocular inflammatory disorders associated with systemic symptoms.

Japanese guidelines for allergic conjunctival diseases 2020.

The definition, classification, pathogenesis, test methods, clinical findings, criteria for diagnosis, and therapies of allergic conjunctival disease are summarized based on the Guidelines for Clinical Management of Allergic Conjunctival Disease 2019. Allergic conjunctival disease is defined as "a conjunctival inflammatory disease associated with a Type I allergy accompanied by some subjective or objective symptoms." Allergic conjunctival disease is classified into allergic conjunctivitis, atopic keratoconjunctivitis, vernal keratoconjunctivitis, and giant papillary conjunctivitis. Representative subjective symptoms include ocular itching, hyperemia, and lacrimation, whereas objective symptoms include conjunctival hyperemia, swelling, folliculosis, and papillae. Patients with vernal keratoconjunctivitis, which is characterized by conjunctival proliferative changes called giant papilla accompanied by varying extents of corneal lesion, such as corneal erosion and shield ulcer, complain of foreign body sensation, ocular pain, and photophobia. In the diagnosis of allergic conjunctival diseases, it is required that type I allergic diathesis is present, along with subjective and objective symptoms accompanying allergic inflammation. The diagnosis is ensured by proving a type I allergic reaction in the conjunctiva. Given that the first-line drug for the treatment of allergic conjunctival disease is an antiallergic eye drop, a steroid eye drop will be selected in accordance with the severity. In the treatment of vernal keratoconjunctivitis, an immunosuppressive eye drop will be concomitantly used with the abovementioned drugs.